Other Events ·
NYSE notifies Annovis Bio of non-compliance with $50M market cap and equity listing standards
ANVSAnnovis Bio, Inc.
The New York Stock Exchange notified Annovis Bio that it is no longer in compliance with continued listing standards due to a 30-day average market capitalization of approximately $48.4 million and a stockholders' deficit of $(4.3) million as of June 30, 2026. The company must submit a plan within 45 days to regain conformity within nine months or face delisting proceedings. Trading continues under the symbol ANVS with a .BC designation indicating non-compliance. Annovis Bio is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases.